Identification | Back Directory | [Name]
N-Butyl-1-deoxygalactonojirimycin | [CAS]
141206-42-0 | [Synonyms]
OGT-923) Lucerastat ACT-434964 N-Butyl-1-deoxygalactonojirimycin Lucerastat
(N-Butyldeoxygalactonojirimycin (2R,3S,4R,5S)-1-Butyl-2-(hydroxyMethyl)-3,4,5-piperidinetriol 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3S,4R,5S)- (2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)piperidine-3,4,5-triol N-(But-1-yl)deoxygalactonojirimycin, (2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)-3,4,5-trihydroxypiperidine | [Molecular Formula]
C10H21NO4 | [MDL Number]
MFCD00269939 | [MOL File]
141206-42-0.mol | [Molecular Weight]
219.28 |
Chemical Properties | Back Directory | [Melting point ]
123-124°C | [Boiling point ]
394.7±42.0 °C(Predicted) | [density ]
1.234±0.06 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under Inert Atmosphere | [solubility ]
DMF: 20 mg/mL; DMSO: 30 mg/mL; Ethanol: 5 mg/mL; PBS (pH 7.2): 10 mg/mL | [form ]
A crystalline solid | [pka]
13.72±0.70(Predicted) | [color ]
White to yellow | [Stability:]
Hygroscopic |
Hazard Information | Back Directory | [Chemical Properties]
White to Off-White Solid | [Uses]
An extremely potent and selective a-D-galactosidase inhibitor. A selective inhibitior of GlcCer synthesis. | [in vivo]
Lucerastat (1200 mg/kg/day food admix), a GCS inhibitor, reduces Gb3 in the absence of residual-GalA activity[2]. Animal Model: | Fabry mice (Gla-/0 and Gla-/-, n = 5 or 6 for each gender)[2]. | Dosage: | 1200 mg/kg/day food admix. | Administration: | Food admix for 20 weeks. | Result: | Reduced lipid storage in two major organs affected by FD: mean Gb3 in the kidneys (-33%, p<0.01). and α-galactose- terminated glycosphingolipids in the dorsal root ganglia (-48%, p<0.05). In the liver of the Fabry mice, mean glucosylceramide (GlcCer (24:0)) was reduced (-59%, p<0.001) in addition to Gb3 (24:1) (-37%, p<0.05) demonstrating substrate reduction through GCS inhibition. |
| [storage]
Store at -20°C |
|
|